Kagocel: Objective Data was Obtained
Within the framework of international project “Treatment of ARVI and Influenza in Routine Clinical Practice” postmarketing study of Kagocel was conducted. These unprecedented large-scale studies were sponsored by NIARMEDIC on its own initiative, one of founders and active participant of NP Kaluga Pharmaceutical Cluster.
The study was aimed at collecting data on effectiveness and safety of Kagocel, and to obtain objective data important to understand influenza and other ARVI in routine clinical practice.
That project of International Community of Internal Medicine in cooperation with Eurasia Community of Infectious Disease Specialists and First Moscow State Medical University named after I.M. Sechenov is performed from November 2013. The data obtained during three years are unprecedented in scale. The program involved over 18000 patients (18 to 93 years) with established diagnosis of ARVI and influenza. The researchers included primary care physicians. Statistical processing of data and clinical interpretation is partially managed by specialists from the First Moscow State Medical University. The study received five approvals of ethical committees, including international approval by Freiburg Ethics Committee.